"Kaleida Health is the largest healthcare provider in Western New York, serving the area’s eight counties with state-of-the-art technology and comprehensive healthcare services. Its expert, compassionate healthcare professionals are committed to providing the best possible outcomes and experience for patients and visitors. More than one million sick or injured patients choose a Kaleida Health facility annually, including Bradford Regional Medical Center, Buffalo General Medical Center/Gates Vascular Institute, DeGraff Medical Park, Millard Fillmore Suburban Hospital, John R. Oishei Children’s Hospital and Olean General Hospital."

During the past decade, Kaleida Health/University of Buffalo conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kaleida Health/University of Buffalo" #1 sponsor was "Actelion" with 2 trials, followed by "Activ Surgical" with 1 trials sponsored, "Brigham and Women's Hospital" with 1 trials sponsored, "Medtronic Neurovascular Clinical Affairs" with 1 trials sponsored and "Standard Bariatrics" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kaleida Health/University of Buffalo" #1 collaborator was "Abbott Medical Devices" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator, "Northwestern University" with 1 trials as a collaborator, "Quintiles, Inc." with 1 trials as a collaborator and "Roche Diagnostics" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Kaleida Health/University of Buffalo" are "Pulmonary Arterial Hypertension" (2 trials), "Acute Cholecystitis" (1 trials), "Colorectal Cancer" (1 trials), "Coronary Artery Disease" (1 trials) and "Diverticulitis, Colonic" (1 trials). Many other conditions were trialed in "Kaleida Health/University of Buffalo" in a lesser frequency.

Most popular intervention types in "Kaleida Health/University of Buffalo" are "Device" (3 trials) and "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "ActivSight" (1 trials), "Bosentan" (1 trials), "Commercial Ventavis® (iloprost)" (1 trials), "Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device" (1 trials) and "Sildenafil" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kaleida Health/University of Buffalo" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Kaleida Health/University of Buffalo". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 3 completed trials in Kaleida Health/University of Buffalo, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Kaleida Health/University of Buffalo, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".